The value of cOPN is unique as a possible biomarker for risk of disease damage in SLE; in this role it is providing additional information by identifying patients who would require closer clinical follow up over time, in comparison with established biomarkers of impending disease flare such as NGAL. Here, LCN2 is linked to systemic lupus erythematosus.